Hepatitis b screening before chemotherapy: A survey of practitioners' knowledge, beliefs, and screening practices

Journal of Oncology Practice

Volumn 8, Issue 6, 2012, Pages 325-328

  Lee, Ronita S M ^a   Bell, Chaim M ^a   Singh, Jeffrey M ^a   Hicks, Lisa K ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL PRACTICE; FEMALE; HEALTH BELIEF; HEALTH CARE SURVEY; HEMATOLOGIC MALIGNANCY; HEMATOLOGIST; HEPATITIS B; HUMAN; MALE; MEDICAL SPECIALIST; ONCOLOGIST; PHYSICIAN; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PROFESSIONAL KNOWLEDGE; QUESTIONNAIRE; RISK FACTOR; SCREENING TEST; SOLID TUMOR; VIRUS REACTIVATION;

ADULT; ANTINEOPLASTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; CANADA; CARRIER STATE; CLINICAL COMPETENCE; FEMALE; HEALTH CARE SURVEYS; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROFESSIONAL PRACTICE; RISK FACTORS; VIRUS ACTIVATION;

EID: 84875969791     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2012.000597     Document Type: Article

References (33)

1. World Health Organization 2008: Hepatitis B. http://www.who.int/ mediacentre/factsheets/fs204/en
2. Weinbaum CM, Williams I, Mast EE, et al: Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recommend Rep 57:1-20, 2008
3. Minuk G, Uhanova J: Chronic hepatitis B infection in Canada. Can J Infect Dis 12:351-356, 2001
4. Liang R, Lau GK, Kwong YL: Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: A review of the problem. J Clin Oncol 17:394-398, 1999
5. Yeo W, Ho WM, Hui P, et al: Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat 88:209-215, 2004
6. Dai MS, Wu PF, Shyu RF, et al: Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int 24:540-546, 2004
7. Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G: Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumors. Br J Cancer 81:69-74, 1999
8. Yeo W, Chan PK, Zhong S, et al: Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol 62:299-307, 2000
9. Idilman R, Arat M, Soydan E, et al: Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat 11:141-147, 2004
10. Lok AS, Liang RH, Chiu EK, et al: Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: Report of a prospective study. Gastroenterology 100:182-188, 1999
11. Cheng AL, Hsiung CA, Su IJ, et al: Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 37:1320-1328, 2003
12. Hsu C, Hsiung CA, Su IJ, et al: A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial. Hepatology 47:844-853, 2008
13. Yeo W, Chan PK, Ho WM, et al: Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 22:927-934, 2004
14. Li YH, He YF, Jiang WQ, et al: Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 106:1320-1325, 2006
15. Loomba R, Rowley A, Wesley R, et al: Systematic review: The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148:519-528, 2008
16. Ziakas PD, Karsaliakos P, Mylonakis E: Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: A meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 94:998-1005, 2009
17. Lubel JS, Testro AG, Angus PW: Hepatitis B virus reactivation following immunosuppressive therapy: Guidelines for prevention and management. Intern Med J 37:705-712, 2007
18. Katz LH, Fraser A, Gafter-Gvili, et al: Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: Systematic review and meta-analysis. J Viral Hepat 15:89-102, 2008
19. Sherman M, Shafran S, Burak K, et al: Management of chronic hepatitis B: Consensus guidelines. Can J Gastroenterol 21:5C-24C, 2007 (suppl)
20. Artz AS, Somerfield MR, Feld JJ, et al: American Society of Clinical Oncology provisional clinical opinion: Chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 28:3199-3202, 2010
21. Canadian Medical Association 2012: Statistical information on Canadian physicians: Physicians by province/territory, subspecialty, Canada. http://www.cma.ca/multimedia/CMA/Content-Images/Inside-cma/Statistics/ 01Spec&Prov.pdf
22. Hosmer DW, Lemeshow S: Applied Logistic Regression (ed 2). New York, NY, Wiley, 2000
23. Austin PC, Tu JV: Automated variable selection methods for logistic regression produced unstable models for predicting acute myocardial infarction mortality. J Clin Epidemiol 57:1138-1146, 2004
24. Centers for Disease Control and Prevention 2012: Infectious diseases related to travel. http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3- infectiousdiseases-related-to-travel/hepatitis-b.htm
25. Tran TT, Rakoski MO, Martin P, et al: Screening for hepatitis B in chemotherapy patients: Survey of current oncology practices. Aliment Pharmacol Ther 31:240-246, 2010
26. Chang MH: Hepatitis B virus infection. Semin Fetal Neonatal Med 12:160-167, 2007
27. Lubel JS, Angus PW: Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: Diagnosis and management. J Gastroenterol Hepatol 25:864-871, 2010
28. Liu CJ, Chen PJ, Chen DS, et al: Hepatitis B virus reactivation in patients receiving cancer chemotherapy: Natural history, pathogenesis, and management. Hepatol Int [epub ahead of print on June 14, 2011]
29. Bikdeli B, Sharif-Kashani B, Raeissi S, et al: Chest physicians' knowledge of appropriate thromboprophylaxis: Insights from the PROMOTE study. Blood Coagul Fibrinolysis 22:667-672, 2011
30. Lurie N, Slater J, McGovern P, et al: Preventive care for women: Does the sex of the physician matter? N Engl J Med 329:478-482, 1993
31. Lee R, Vu K, Bell CM, et al: Screening for hepatitis B surface antigen before chemotherapy: Current practice and opportunities for improvement. Curr Oncol 17:32-38, 2010
32. Day FL, Karnon J, Rischin D: Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumours. J Clin Oncol 29:3270-3277, 2011
33. Zurawska U, Hicks LK, Woo G, et al: Screening for hepatitis B virus (HBV) prior to chemotherapy: A cost-effectiveness analysis. J Clin Oncol 29:398S, 2011 (suppl; abstr 6059)